Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Rare Diseases Weight Loss Treatment Elinzanetant Eli Lilly Azelaprag Cancer Treatments Obesity Treatments Vibozilimod Oveporexton Phase 3 Trials Personalized Medicine Enlicitide Limb-Girdle Muscular Dystrophy Diabetic Macular Edema Tolebrutinib Inflammatory Diseases Novo Nordisk Aleniglipron AD109 Masitinib for ALS AstraZeneca Inflammatory Bowel Disease Biopharmaceuticals

Law Firms Press Soleno Investors to Seek Lead Role in Securities Suit by May 5

Plaintiffs say Soleno hid safety risks tied to its only drug.

Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline

Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress